Barreto, PatríciaVieira, PedroDias, LeonidioAlmeida, ManuelaPedroso, SofiaMartins, La SaleteHenriques, António CastroBINI ANTUNES, MARIKA2020-02-202020-02-202015Port J Nephrol Hypert 2015; 29(4): 332-337http://hdl.handle.net/10400.26/31475Kidney transplantation is the optimal treatment of end -stage renal disease (ESRD) improving survival and quality of life for most recipients. In our country, potential living donors have been refused due to the ABO incompatibility barrier. However, ABO -incompatible living donor kidney transplant is presently common practice in several countries with good outcomes. The authors describe a case of a 49 -year -old female patient, with chronic kidney disease due to autosomal dominant polycystic kidney disease, who had started haemodialysis 10 months before and with blood group O. The living donor was a 53 -year -old sister with blood group B. The desensitization protocol was based on rituximab and plasmapheresis. The induction protocol used was basiliximab, tacrolimus, mofetil mycophenolate and metilprednisolone. Five days post -transplant she presented a normal graft function that remained during the eight months follow -up. This case reveals the first ABO incompatible living donor kidney transplant performed in Portugal with excellent outcome.porABO incompatibilitykidney transplantationliving donorPortugaljournal article